These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 17050252)

  • 1. Correlation of residual leukocyte subsets with neutropenic fever during severe leukopenia after high-dose chemotherapy and autologous stem cell transplantation.
    Schnabel B; Schmidmaier R; Franke D; Emmerich B; Straka C
    Cytotherapy; 2006; 8(5):473-9. PubMed ID: 17050252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
    Steingrimsdottir H; Gruber A; Björkholm M; Svensson A; Hansson M
    Haematologica; 2000 Aug; 85(8):832-8. PubMed ID: 10942930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4(+) CD28(+) lymphocytes on day 5 after high-dose melphalan for multiple myeloma predict a low risk of infections during severe neutropenia and are associated with the number of reinfused T lymphocytes of the autologous stem cell graft.
    Schmidmaier R; Then C; Schnabel B; Oduncu F; Baumann P; Straka C
    Cytotherapy; 2011 Sep; 13(8):987-92. PubMed ID: 21599548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma.
    Fenk R; Hieronimus N; Steidl U; Bruns I; Graef T; Zohren F; Ruf L; Haas R; Kobbe G
    Exp Hematol; 2006 Oct; 34(10):1296-302. PubMed ID: 16982322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Helper T cells (CD3 + /CD4 + ) within the autologous peripheral blood stem cell graft positively correlate with event free survival of multiple myeloma patients.
    Schmidmaier R; Oversohl N; Schnabel B; Straka C; Emmerich B
    Exp Oncol; 2008 Sep; 30(3):240-3. PubMed ID: 18806749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular immune responses in multiple myeloma patients with treatment-induced cytopenia early after high-dose chemotherapy and autologous peripheral blood stem cell transplantation.
    Wendelbo Ø; Nesthus I; Sjo M; Ernst P; Bruserud Ø
    Leuk Res; 2004 May; 28(5):461-8. PubMed ID: 15068899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Large-scale expansion and transplantation of CD34(+) hematopoietic cells: in vitro and in vivo confirmation of neutropenia abrogation related to the expansion process without impairment of the long-term engraftment capacity.
    Boiron JM; Dazey B; Cailliot C; Launay B; Attal M; Mazurier F; McNiece IK; Ivanovic Z; Caraux J; Marit G; Reiffers J
    Transfusion; 2006 Nov; 46(11):1934-42. PubMed ID: 17076849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients.
    Martino M; Praticò G; Messina G; Irrera G; Massara E; Messina G; Console G; Iacopino P
    Eur J Haematol; 2006 Nov; 77(5):410-5. PubMed ID: 16930141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematopoietic engraftment of dimethyl sulfoxide-depleted autologous peripheral blood progenitor cells.
    Akkök CA; Holte MR; Tangen JM; Ostenstad B; Bruserud O
    Transfusion; 2009 Feb; 49(2):354-61. PubMed ID: 18980622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A preliminary analysis of the balance between Th1 and Th2 cells after CD34+ cell-selected autologous PBSC transplantation.
    Endo T; Sato N; Koizumi K; Nishio M; Fujimoto K; Yamamoto S; Sakai T; Bohgaki T; Sawada K; Koike T
    Cytotherapy; 2004; 6(4):337-43. PubMed ID: 16146886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infections in patients managed at home during autologous stem cell transplantation for lymphoma and multiple myeloma.
    Herrmann RP; Trent M; Cooney J; Cannell PK
    Bone Marrow Transplant; 1999 Dec; 24(11):1213-7. PubMed ID: 10642811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cell counts and their subsets during treatment of multiple myeloma.
    Kovarova L; Buchler T; Pour L; Zahradova L; Ocadlikova D; Svobodnik A; Penka M; Vorlicek J; Hajek R
    Neoplasma; 2007; 54(4):297-303. PubMed ID: 17822319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous infusion of ceftazidime for patients with breast cancer and multiple myeloma receiving high-dose chemotherapy and peripheral blood stem cell transplantation.
    Egerer G; Goldschmidt H; Hensel M; Harter C; Schneeweiss A; Ehrhard I; Bastert G; Ho AD
    Bone Marrow Transplant; 2002 Oct; 30(7):427-31. PubMed ID: 12368954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma.
    Wallington-Beddoe CT; Gottlieb DJ; Garvin F; Antonenas V; Sartor MM
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1386-93. PubMed ID: 19822297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The serum IL-12:IL-6 ratio reliably distinguishes infectious from non-infectious causes of fever during autologous stem cell transplantation.
    Tuma R; Almyroudis N; Sohn S; Panageas K; Rice R; Galinkin D; Blain M; Montefusco M; Pamer E; Nimer S; Kewalramani T
    Cytotherapy; 2006; 8(4):327-34. PubMed ID: 16923608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors.
    Reich G; Mapara MY; Reichardt P; Dörken B; Maschmeyer G
    Bone Marrow Transplant; 2001 Mar; 27(5):525-9. PubMed ID: 11313687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients.
    Miceli MH; Dong L; Grazziutti ML; Fassas A; Thertulien R; Van Rhee F; Barlogie B; Anaissie EJ
    Bone Marrow Transplant; 2006 May; 37(9):857-64. PubMed ID: 16532017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: risk factors analysis and outcome.
    Gil L; Styczynski J; Komarnicki M
    Infection; 2007 Dec; 35(6):421-7. PubMed ID: 17926001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
    Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
    Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.